Apricoxib

Apricoxib is an experimental anticancer drug. It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer. Development was abandoned in 2015 due to poor clinical trial results. Apricoxib is an experimental anticancer drug. It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer. Development was abandoned in 2015 due to poor clinical trial results.